Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. 2013

Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
Department of Microbiology-Mycology, ACIAM, Barcelona, Spain. acarrillo@aciam.es

Sertaconazole is a useful antifungal agent against mycoses of the skin and mucosa, such as cutaneous, genital and oral candidiasis and tinea pedis. Its antifungal activity is due to inhibition of the ergosterol biosynthesis and disruption of the cell wall. At higher concentrations, sertaconazole is able to bind to nonsterol lipids of the fungal cell wall, increasing the permeability and the subsequent death of fungal cells. Fungistatic and fungicidal activities on Candida are dose-dependent. The antifungal spectrum of sertaconazole includes deramophytes, Candida, Cryptococcus, Malassezia and also Aspergillus, Scedosporium and Scopulariopsis. Sertaconazole also shows an antimicrobial activity against streptococci, staphylococci and protozoa (Trichomonas). In clinical trials including patients with vulvovaginal candidiasis, a single dose of sertaconazole produced a higher cure rate compared with other topical azoles such as econazole and clotrimazole, in shorter periods. Sertaconazole has shown an anti-inflammatory effect that is very useful for the relief of unpleasant symptoms.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002175 Candida A genus of yeast-like mitosporic Saccharomycetales fungi characterized by producing yeast cells, mycelia, pseudomycelia, and blastophores. It is commonly part of the normal flora of the skin, mouth, intestinal tract, and vagina, but can cause a variety of infections, including CANDIDIASIS; ONYCHOMYCOSIS; VULVOVAGINAL CANDIDIASIS; and CANDIDIASIS, ORAL (THRUSH). Candida guilliermondii var. nitratophila,Candida utilis,Cyberlindnera jadinii,Hansenula jadinii,Lindnera jadinii,Monilia,Pichia jadinii,Saccharomyces jadinii,Torula utilis,Torulopsis utilis,Monilias
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
June 2005, Expert review of anti-infective therapy,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
December 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
May 1992, Arzneimittel-Forschung,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
May 1992, Arzneimittel-Forschung,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
January 1993, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
January 1991, Clinics in dermatology,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
June 2017, European review for medical and pharmacological sciences,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
January 2023, PloS one,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
January 1989, Clinical therapeutics,
Alfonso Javier Carrillo-Muñoz, and Cristina Tur-Tur, and Gustavo Giusiano, and Cristina Marcos-Arias, and Elena Eraso, and Nerea Jauregizar, and Guillermo Quindós
October 2001, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!